Background: The role of flow cytometry in diagnosis and management of Hodgkin lymphoma (HL) remains limited. As knowledge emerges of the tumor microenvironment in this disease, various methods are being evaluated in its study. This study examines the microenvironment using flow cytometry to assess differences between subtypes and clinicopathologic correlates.
INTRODUCTION
With combined modality treatment, Hodgkin lymphoma (HL) in children has an event-free survival at 5 years of about 80%. Despite this success, those with relapsed or refractory disease have poor outcomes.
Additionally, currently, at diagnosis, only stage predicts outcome and determines those who receive intensified therapy. Current trials are attempting to use individualized risk-adapted therapy in order to maximize treatment response and minimize long-term sequelae. To this end, biomarkers of disease behavior have become increasingly important.
Few studies have examined HL histologic subtype and its relationship with outcome. These have found an association between mixed cellularity (MC) subtype and superior outcome, 1,2 and, conversely, linked stage IV disease 3, 4 and nodular sclerosis (NS) 2 subtype 4 with Abbreviations: ALC, absolute lymphocyte; CCR, continuous complete remission; CTL, cytotoxic T lymphocyte; HL, Hodgkin lymphoma; HRS, Hodgkin Reed-Sternberg; MC, mixed cellularity; NS, nodular sclerosis; WBC, white blood cell increased risk of relapse. In developing countries, EBV-associated HL is more common, tends to occur in younger patients, and is more often MC subtype. 5, 6 Recent studies have linked tumor associated macrophages with outcome. [7] [8] [9] [10] [11] [12] [13] Higher numbers of CD68 + macrophages within tumor tissues were associated with shorter progression-free survival. 7, 8, 10, 11, 14 CD163 and CSF1R expression have also been linked to survival. 13 Emerging data also highlights the potential relationship between the number of regulatory T-cells and outcome in adults. 15 Similar data in children are limited and contradictory 12, 16 and the biologic features shared by patients with relapsed or refractory disease are largely unidentified.
Flow cytometry is useful in diagnosing non-Hodgkin lymphoma, but its use has been limited in HL. Few studies have found patterns in the immunohistochemical profile [17] [18] [19] [20] [21] [22] [23] [24] [25] that may be specific to HL. The immunophenotype of EBV-positive tumors has also been shown to be modulated by the virus. 12, 24, 26 Understanding the relationship between the microenvironment and the behavior of HL may allow us to identify biomarkers for disease.
Additionally, flow cytometry may help diagnose HL. Here, we describe our analysis of tumor tissue by flow cytometry, in which we found that specific aspects of the microenvironment were associated with clinical characteristics and outcome. 
MATERIALS AND METHODS

FLOW CYTOMETRY
Lymph node biopsy specimens were mechanically dissociated to obtain 
STATISTICAL METHODS
Data were analyzed with Student's t-tests, nonparametric MannWhitney U and Kruskal-Wallis tests, and Pearson's correlation coefficient. Logistic regression models were used for both univariate and multivariate analyses. Receiver operating characteristics (ROC) curves were created using outcome of relapsed/refractory or continuous complete remission (CCR) assessed at 2 years from completion of treatment to assess best cut-off values for HLA-DR/CD38 copositive lymphocyte percentage. Cross-validation was performed using the "leave one out" method. Survival was analyzed with the Kaplan-Meier method. Cox proportional hazard regression was used for both univariate and multivariate analysis. Data were analyzed with the SAS 9.3 statistical software program (Cary, NC).
RESULTS
There were 31 qualifying children; one case of nodular lymphocyte predominant subtype was excluded, and the remaining 30 cases of classical HL were analyzed. The histologic subtype was NS in 21, median age 14 years (17 female), mixed cellular (MC) in six, median age 11 years (1 female), and undetermined in three (Table 1 ). All patients were treated on regimens based on risk classification, regardless of histologic subtype. While T cells predominated in the NS samples, the infiltrate in the MC samples was balanced between T and B cells ( Table 2 ).
The mean proportion of CD4-positive T lymphocytes was significantly higher in the NS subtype and, conversely, the mean proportion of CD8-positive cells was significantly higher in the MC subtype. Consistently, the CD4/CD8 ratio was significantly higher in NS. All six MC tumors were in situ EBV-positive, compared to only 24% (5 of 21) of NS tumors (P = 0.008). Further analysis of NS cases by in situ EBV status revealed that the CD4/CD8 ratio was intermediate to those of MC group and EBV-negative NS cases (5.5).
The mean white blood cell (WBC) counts and absolute lymphocyte (ALC) counts in the peripheral blood at the time of diagnosis were significantly higher in children with NS than in those with MC (Table 2 ).
There was a positive correlation between WBC and CD4/CD8 ratio and a negative one between WBC and HLA-DR/CD38 copositive lymphocyte proportion (r = 0.7, P < 0.0001 and r = -0.51 and P = 0.004, respectively) both in the entire population as well as within the NS subgroup (r = 0.65, P = 0.002 and r = -0.49, P = 0.015, respectively). There was no correlation between WBC and CD3 or CD19 proportions in tumor tissue.
The proportion of patients with primary CCR was significantly higher in the MC group (P = 0.009). Higher hemoglobin concentrations at diagnosis were associated with primary CCR (P = 0.07). Higher HLA-DR/CD38 copositive lymphocyte percentage was also associated with primary CCR status (P = 0.002) in the entire study group and when analyzed for the NS group (P = 0.003). There was no significant difference in HLA-DR/CD38 copositive lymphocyte proportion by subtype.
Furthermore, HLA-DR/CD38 copositive lymphocyte percentage negatively correlated with the CD4/CD8 ratio (r = -0.59; P = 0.004) in the whole group and in the NS group (r = -0.62, P = 0.01). The area under the ROC curve for predicting relapse or refractoriness using HLA-DR/CD38 copositive lymphocyte percentage cut-offs was 0.83 (95% CI, 0.67-1; P < 0.001; Figure 1 ), indicating that this marker could potentially predict patients who will have refractory or relapsed disease. This was supported by cross-validation.
The 5-year event-free survival for all children was 69%. Survival analysis showed that the event-free survival was lower for those with NS subtype, which was expected given that there were no relapses in
TA B L E 1 Characteristics of 30 children with Hodgkin lymphoma by histologic subtype
Characterisitics
Nodular sclerosis (n = 21) Mixed cellularity (n = 6) Undetermined (n = 3) Sex, n (%) patients with MC subtype. However, event-free survival differed significantly among four groups based on the percentage of lymphocytes copositive for HLA-DR/38 (P = 0.017; Figure 2) . Moreover, the hazard ratio for relapse was 0.54 (95% CI, 0.33-0.87; P = 0.011) for every 10% increase in HLA-DR/CD38 copositive lymphocytes. In multivariate analysis, accounting for age, sex, stage and subtype, percentage of HLA-DR/CD38 copositive lymphocyte remained a predictive factor (P = 0.011).
DISCUSSION
The Higher numbers of CD8 + T-cells in MC tumor samples as evaluated by immunohistochemistry was also seen in a previous study. 24 We observed higher CD4/CD8 ratios in tissue, and higher WBC and ALC counts in the peripheral blood in NS cases, compared to MC cases. We also found a correlation between CD4/CD8 ratio and WBC, indicating HL samples, which we noted in the patients with MC subtype, all of which were EBV positive. 26 We did not note a significant difference, however, when comparing EBV-positive and EBV-negative NS cases.
In another study, Barros et al. found that CD8 + T cells were increased in MC tumor samples by immunohistochemistry, as well as in EBVpositive cases, similar to our findings. 24 Interestingly, they observed a trend toward worse PFS for children with MC subtype in contrast to our observation.
Our findings also indicate a relationship between tumor microenvironment characteristics, as assessed by flow cytometry, and clinical outcomes. A recent study of adults with HL found a correlation between CD8-positive lymphocyte proportions and freedom from treatment failure, 29 although previous studies were contrasting. 30 We noted that children with MC subtype, whose tumor samples had higher percentages of CD8-positive T cells, had a better CCR rate, although CD8-positive lymphocyte proportion itself was not associated with outcome in this study. However, we did observe that patients whose tumors had a higher percentage of activated HLA-DR/CD38 copositive lymphocytes had higher CCR rates, indicating that this proportion may predict relapse or refractoriness. Additionally, the proportion of HLA-DR/CD38 copositive lymphocytes was negatively correlated with the CD4/CD8 ratio; however, we do not have data as to whether these lymphocytes are CD4 or CD8 positive.
The association between HLA-DR/CD38 copositive lymphocyte proportion and outcome has not previously been reported. The coexpression of HLA-DR and CD38 on lymphocytes is a marker of activation. We postulate that these findings together may be indicators for tumors that are less immune evasive, that is, less successfully inhibitive of cytotoxic T lymphocytes and activated CD4 positive T cells. This is further supported by findings in recent studies evaluating the highly successful checkpoint inhibitors, which have shown that PD-1 blockade acts by promoting T-cell activation. 31 Biomarkers for response to checkpoint inhibitors in HL remain elusive, 32 and this will be evaluated in future studies.
These findings may indicate a better outcome in children with HL who have higher numbers of activated CD8-positive T lymphocytes in the tumor microenvironment and could potentially lead to therapeutic approaches that can exploit these alterations.
CONCLUSIONS
Flow cytometry can characterize the tumor microenvironment in HL, and the percentage of HLA-DR/CD38 copositive lymphocytes may be a biomarker for relapse and refractoriness in children with HL.
